A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04624971

Enrollment

2000

Registered

2020-11-12

Start date

2020-11-30

Completion date

2020-11-30

Last updated

2020-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B Cell Lymphoma

Brief summary

The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically confirmed diagnosis of CD20+ DLBCL

Exclusion criteria

* primary central nervous system lymphoma * double-hit lymphoma

Design outcomes

Primary

Measure	Time frame
Overall survival	5-year

Countries

China

Contacts

Primary ContactQingqing Cai, MD

caiqq@sysucc.org.cn0086-20-87342823

Outcome results